Florence, Italy – March 9, 2026
Menarini Group, one of Europe’s leading pharmaceutical companies, has reported strong financial growth in 2025 with revenue reaching €4.887 billion, marking a 6.2% increase compared with the previous year. The company attributed the growth to strong global demand for medicines, expansion in oncology treatments, and increased investment in research and development, while also emphasizing the strategic role of artificial intelligence in accelerating drug discovery. As Menarini celebrates its 140th anniversary, the company highlighted a long-term strategy focused on innovation, talent development, and advanced digital technologies, even as the global pharmaceutical sector faces geopolitical tensions, regulatory pressures, and increased competition from major global players.
Strong Global Growth and Expanding Pharmaceutical Portfolio
Menarini operates across 140 countries worldwide and sold approximately 905 million pharmaceutical units in 2025, reflecting strong international demand for its medicines and healthcare products. The company’s global commercial footprint continues to expand, with the United States emerging as the group’s second-largest market, while growth in Europe, the Middle East, and Central America remained solid despite economic and geopolitical challenges.
Company leadership noted that currency fluctuations, particularly the euro–dollar exchange rate, had a negative financial impact of nearly €60 million during the year, yet overall business performance remained resilient. The company also reported EBITDA between €440 million and €470 million, demonstrating strong operational stability in a competitive global pharmaceutical market.
One of the most notable growth areas for Menarini in 2025 was oncology, where revenue increased by €101 million to reach €630 million. The company described oncology as one of its most dynamic therapeutic areas, where it competes directly with some of the world’s largest pharmaceutical companies. This growth reflects rising global demand for cancer therapies and ongoing innovation in precision medicine, positioning oncology as a central pillar of Menarini’s long-term strategy.
Advertisement
Major Investment in Research, Innovation and Talent
Innovation remains a key driver of Menarini’s expansion strategy. In 2025 the company invested €540 million in research and development, demonstrating its commitment to advancing new medicines and maintaining a strong pharmaceutical pipeline. In addition to R&D investments, the company allocated €120 million to technology development, digital infrastructure, and cybersecurity, strengthening its technological capabilities across global operations.
As a privately owned, family-led pharmaceutical company, Menarini emphasized that its investment strategy focuses on self-financed growth and long-term innovation, allowing the company to reinvest profits into scientific research without relying heavily on external funding sources. Leadership stressed that sustained R&D investment is essential for developing breakthrough therapies and maintaining competitiveness in the rapidly evolving pharmaceutical landscape.
The company also highlighted its workforce diversity and talent strategy. In 2025, women accounted for 50.7% of Menarini’s global workforce of 17,800 employees, marking the first time women represented the majority of staff within the organization. The company described this milestone as evidence of its merit-based culture and commitment to attracting highly skilled scientific and technical professionals to support its global research and commercial operations.
Artificial Intelligence Accelerating Drug Discovery
Artificial intelligence is becoming an increasingly important component of Menarini’s research strategy. According to company leadership, AI-driven technologies are transforming pharmaceutical research by dramatically reducing the time required to identify potential drug candidates. Traditionally, discovering a new medicine can take between five and ten years, but AI-assisted discovery tools may reduce this timeline to as little as two to three years, accelerating the development of innovative therapies.
Through its collaboration with AI-powered drug discovery platforms, Menarini is applying machine learning to screen large chemical libraries, identify promising molecular structures, and optimize candidate compounds before clinical development begins. This approach allows researchers to analyze complex biological data more efficiently and identify new therapeutic targets with greater precision.
AI is also being used to improve clinical trial design, patient identification, and regulatory processes, potentially reducing development costs and increasing the probability of successful drug approvals. Company executives believe these advances could usher in a “renaissance in healthcare,” enabling pharmaceutical companies to bring new treatments to patients more rapidly than ever before.
Despite technological progress, Menarini executives also warned that geopolitical tensions, rising manufacturing costs, and regulatory challenges in Europe could influence the future competitiveness of the pharmaceutical industry. Issues such as supply chain disruptions, intellectual property policies, and global economic uncertainty remain key concerns for pharmaceutical companies operating in international markets.
Nevertheless, the company remains confident that continued investment in research, talent, and advanced technologies such as artificial intelligence will strengthen its position in the global pharmaceutical sector. With a growing oncology portfolio, expanding global presence, and a strong innovation pipeline, Menarini aims to remain at the forefront of pharmaceutical research and healthcare transformation in the years ahead.
z
Source: Menarini Group press release
